The company will also acquire and assume manufacturing sites in the US located in Laurinburg, North Carolina and Van Buren, Arkansas
Bulgaria headquartered Huvepharma, a global animal health company, will acquire certain assets from Zoetis, which include products and two owned and one leased US manufacturing sites. The assets associated with this deal involve an international portfolio of medicated feed additives, including Albac (excluding the USA market) and bio-Cox / Salinomax as well as InovocoxEM1, leading coccidiosis vaccine for broilers.
Along with these products, Huvepharma will acquire and assume manufacturing sites in the US located in Laurinburg, North Carolina and Van Buren, Arkansas. Other assets included in the acquisition are major brands of water soluble veterinary products; R-Pen, Oxytet, Sul-Q-Nox, CTC, Lincomycin, Poultry Sulfa and Neo-Sol including the formulation facility located in Longmont, Colorado. Additional pharmaceuticals assets were also acquired that are predominately sold in Europe and include Lincocin Forte, Stockade, Bacivet, Combiotic and Quadrisol. Employees at the three manufacturing sites will be transferred to Huvepharma.
